Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
Over the past two decades, many new variants of targeted therapy for metastatic colorectal cancer (mCRC) had appeared, and significantly increased patient survival. However, there were questions relating to the definition of the optimal sequence and the combination of different drugs. Cytotoxic agen...
Guardado en:
Autores principales: | M. I. Sekacheva, R. I. Nuriev, A. A. Rozhkov, A. V. Semenkov, N. N. Bagmet, A. M. Boroda |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5e4f261f79964feabb01d7d3d9dc1d9c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Regorafenib in metastatic colorectal cancer: more data for clinical decisions
por: Vladislav V. Petkau, et al.
Publicado: (2021) -
Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
por: Marina I. Sekacheva, et al.
Publicado: (2021) -
A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report
por: Simona De Summa, et al.
Publicado: (2021) -
Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Hong Zhou, et al.
Publicado: (2021) -
SHORT-TERM RESULTS OF SIMULTANEOUS SURGERIES AT METASTATIC COLORECTAL CANCER
por: A. S. Zagaynov, et al.
Publicado: (2017)